Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders ...

Alcon announced in early August that it has entered into a definitive merger agreement with Staar, under which Alcon will ...

Broadwood Partners, STAAR's largest shareholder, opposes the Alcon merger, citing board conflicts and rushed decision-making.

If you have been wondering what to do with Alcon stock lately, you are definitely not alone. With shares closing at $61.12 and recent moves showing a 2.0% gain over the past week and a 3.7% increase ...

The special meeting to vote on the company's $1.5 billion sale to Alcon, originally scheduled for today, has been adjourned ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company ...

Millions of contact lens wearers navigating busy schedules and long hours on screens are seeking a balance of comfort and ...

Alcon has experienced robust Q1 growth, driven by double-digit growth in vision care, particularly in the contact lens market. The company's strong revenue growth is attributed to successful product ...

Former Novartis subsidiary Alcon, after targeting the pharmaceutical eye drop scene with a trio of recent drug purchases, is adding another pair of arrows to its ophthalmic quiver. And this time, the ...

Alcon is acquiring Aerie Pharma for $770 million, the third deal in the past two years that brings commercialized glaucoma products to the eyecare giant’s portfolio. According to financial terms ...

Alcon Entertainment “got its ass kicked” financially with the weak box office performance of “Transcendence,” the company’s top executive told TheWrap, saying that the company will lose at least $30 ...